Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1392 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Panli Cardona und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, USA. Hauptthemen laut MEDLINE: Liver-Specific Organic Anion Transporter 1, Solute Carrier Organic Anion Transporter Family Member 1B3, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Sotorasib is a small molecule that irreversibly inhibits the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein with a G12C amino acid substitution mutant protein. The impact of cytochrome P450 (CYP) 3A4 inhibition and induction on sotorasib pharmacokinetics (PKs) was evaluated in 2 separate studies in healthy volunteers (N = 14/study). The impact of CYP3A4 inhibition was interrogated utilizing repeat doses of 200 mg of itraconazole, a strong CYP3A4 inhibitor, on 360 mg of sotorasib PKs. The impact of CYP3A4 induction was interrogated utilizing multiple doses of 600 mg of rifampin, a strong CYP3A4 inducer. Additionally, the impact of organic anion transporting polypeptide (OATP) 1B1/3 inhibition on 960 mg of sotorasib PKs was interrogated after a single dose of 600 mg of rifampin. CYP3A4 inhibition did not significantly impact sotorasib C max but did lead to a 26% increase in sotorasib AUC inf . CYP3A4 induction decreased sotorasib C max by 35% and AUC inf by 51%. OATP1B1/3 inhibition decreased sotorasib C max and AUC inf by 16% and 23%, respectively. These results support that sotorasib can be given together with strong CYP3A4 and OATP1B1/3 inhibitors but the co‐administration of sotorasib and strong CYP3A4 inducers should be avoided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, USA.
Zitieren
APA
Cardona, P., Dutta, S., & Houk, B. (2024). Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1392
Vancouver
Cardona P, Dutta S, Houk B. Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1392
BibTeX
@article{Cardona2024,
author = {Cardona, Panli and Dutta, Sandeep and Houk, Brett},
title = {Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1392}
}
EUVIMED